Odetiglucan
Clinical Trials Overview
1 trials found
About Odetiglucan
Odetiglucan is an investigational medication currently being studied in clinical trials for certain types of metastatic colorectal cancer, specifically those where the cancer has spread mainly to the liver. It is being tested in combination with pembrolizumab, an immunotherapy drug. The goal of these trials is to see if this combination is safe and effective for patients whose cancer has specific genetic characteristics (like being BRAF, KRAS, NRAS, EGFR, and VEGF wild-type, and MSI-H). Odetiglucan is not yet approved for use in colorectal cancer and is only available as part of a clinical trial.
Category
Other Medications
Mechanism
Odetiglucan is a type of medication that is being investigated for its potential to interact with the immune system and potentially affect the tumor microenvironment. The specific way it works is still being studied in clinical trials. It is thought to potentially modulate the immune response or affect the way cancer cells interact with their surroundings.
1
Total Trials
1
Recruiting
0
Active
0
Completed
27
Total Enrollment
1
Countries
med_trials_active_sites
Recruiting sites
1 countries
NCT07082439
Phase 2
Recruiting
27 patients
Medications:
Odetiglucan
Pembrolizumab
This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
United States